MDxHealth (NASDAQ:MDXH) Issues Q2 2025 Earnings Guidance

Key Points

• MDxHealth updated its Q2 2025 earnings guidance to an earnings per share of -0.150, compared to the consensus estimate of -0.117, and provided revenue guidance of $26.6 million, slightly below the consensus estimate of $26.9 million.
• Shares of MDxHealth increased by 0.8% during midday trading, reaching a price of $2.49, with a reported market cap of $117.75 million.
• Analysts have mixed ratings for MDxHealth, with Craig Hallum giving it a "buy" rating and a target price of $8.00, while Wall Street Zen upgraded it to a "hold" rating.

MDxHealth (NASDAQ:MDXH - Get Free Report) issued an update on its second quarter 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of -0.150--0.150 for the period, compared to the consensus EPS estimate of -0.117. The company issued revenue guidance of $26.6 million-$26.6 million, compared to the consensus revenue estimate of $26.9 million.

Analyst Ratings Changes

Several research firms recently weighed in on MDXH. Craig Hallum began coverage on shares of MDxHealth in a research report on Thursday, July 17th. They issued a "buy" rating and a $8.00 price objective on the stock. Wall Street Zen raised MDxHealth to a "hold" rating in a research note on Saturday, May 24th.

MDxHealth Price Performance

MDXH traded down $0.04 during midday trading on Friday, hitting $2.66. The stock had a trading volume of 54,832 shares, compared to its average volume of 97,636. The company has a market cap of $125.79 million, a P/E ratio of -3.02 and a beta of 1.41. The business has a fifty day moving average of $2.26 and a 200 day moving average of $1.92. The company has a debt-to-equity ratio of 13.81, a quick ratio of 1.92 and a current ratio of 2.00. MDxHealth has a 1 year low of $1.35 and a 1 year high of $3.50.

MDxHealth (NASDAQ:MDXH - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). The company had revenue of $26.60 million for the quarter, compared to analysts' expectations of $26.60 million. MDxHealth had a negative net margin of 34.98% and a negative return on equity of 274.67%. As a group, equities analysts forecast that MDxHealth will post -1.15 earnings per share for the current fiscal year.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.